European Pharmaceutical Manufacturer speaks with John McDermott, Vice President of Scientific Consulting at Quotient Sciences, to explore the strategic advantages of partnering with a CRDMO.
John explains how CRDMOs—by integrating the capabilities of CROs and CDMOs—streamline the drug development process, reduce handoffs, and accelerate timelines. He highlights Quotient Sciences’ Translational Pharmaceutics® platform, a pioneering approach that unifies formulation, manufacturing, and clinical testing into a seamless process.
This integration not only enhances efficiency and reduces costs but also enables real-time decision-making and adaptive development strategies, ultimately bringing new therapies to patients faster.
Read the full article on European Pharmaceutical Manufacturer.
"CRDMOs offer a number of strategic and operational benefits for pharmaceutical and biotech companies... By consolidating services under one roof, CRDMOs eliminate the need for multiple handoffs between vendors."
-John McDermott